publication . Other literature type . Article . 2020

DESIGN & MOLECULAR DOCKING STUDIES OF COUMARIN SUBSTITUTED 1, 3, 4-OXADIAZOLES AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS.

Purohit S.S.*, Kulkarni V.H., Joshi S.D.;
Open Access
  • Published: 29 May 2020
  • Publisher: Zenodo
Abstract
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase that mediates the addition of phosphate molecules onto serine and threonine amino acid residues. First discovered in 1980 as a regulatory kinase for its namesake, Glycogen synthase, GSK-3 has since been identified as a kinase for over forty different proteins in a variety of different pathways. GSK-3 has recently been the subject of much research because it has been implicated in a number of diseases, including Type II diabetes (Diabetes mellitus type 2), Alzheimer's Disease, inflammation, cancer, and bipolar disorder. A plethora of GSK-3 inhibitors has been described and most of the effects...
Subjects
Medical Subject Headings: macromolecular substances
free text keywords: GSK-3 Inhibitors, Coumarin Containing 1,3, 4-Oxadiazoles, Design & Molecular Docking., GSK-3 Inhibitors, Coumarin Containing 1,3, 4-Oxadiazoles, Design & Molecular Docking.
Download fromView all 3 versions
Zenodo
Other literature type . 2020
Provider: Datacite
Zenodo
Other literature type . 2020
Provider: Datacite
ZENODO
Article . 2020
Provider: ZENODO
Any information missing or wrong?Report an Issue